- Most Zepbound denials can be appealed with additional medical documentation
- Common denial reasons include BMI thresholds, incomplete records, or step-therapy requirements
- PEAK handles the appeal process, including peer-to-peer reviews with insurance medical directors
- Alternative medications and coverage pathways often exist if initial appeals fail
What the denial means
A prior authorization denial means your insurance plan reviewed your clinician's request to prescribe Zepbound and determined it did not meet their medical necessity criteria. This is not a final decision, and it does not mean you cannot access treatment.
Importantly, a denial is not a judgment about whether you clinically need the medication. It is an administrative determination about whether the submitted documentation met your plan's specific coverage requirements. Those requirements vary significantly between insurers and even between plan types within the same insurer.
Your denial letter should include the specific reason for denial, which helps determine the next steps. At PEAK, we review every denial letter with patients and explain what it means in plain terms before deciding how to proceed.
Check for: (1) the specific denial reason, (2) whether an appeal is available, (3) the appeal deadline (usually 180 days), and (4) contact information for member services. If any of this information is missing or unclear, your clinician's office can request clarification from the insurance plan.
Why prior authorizations get denied
The most common reasons we see for Zepbound denials include:
BMI criteria not met (or not documented)
Most plans require a BMI of 27 or higher with a weight-related comorbidity, or a BMI of 30 or higher without one. If your chart documentation did not clearly state your BMI at the time of the request, the plan may deny it for insufficient evidence — even if you clinically qualify.
Step therapy requirements
Many insurers require patients to try and fail another medication first — often a lower-cost GLP-1 like Wegovy or even older weight loss medications like phentermine. If your plan has step therapy rules and your clinician requested Zepbound without documenting prior medication trials, the request will likely be denied.
Incomplete clinical documentation
Insurers often require evidence of lifestyle modifications (documented nutrition counseling, exercise programs) alongside medication. If the prior authorization submission did not include detailed clinical notes showing these efforts, the plan may deny the request as not meeting medical necessity criteria.
Off-label use
Zepbound (tirzepatide) is FDA-approved for chronic weight management in adults with obesity or overweight with comorbidities. If it was prescribed outside these parameters — for example, for a patient with a BMI under 27 without documented comorbidities — the plan will deny coverage.
Most denials are procedural, not clinical. They reflect gaps in paperwork, not gaps in medical justification.
What to do after a denial
First: don't assume the denial is final. In our experience, most prior authorization denials for GLP-1 medications can be successfully overturned with additional documentation or a peer-to-peer review between your clinician and the insurance medical director.
Here's what happens next at PEAK:
Step 1: Review the denial reason with your clinician
We review the specific denial reason, assess what documentation was missing, and determine whether an appeal is clinically appropriate. If the denial was based on a correctable documentation issue (missing BMI, incomplete comorbidity records), we gather that information for the appeal.
Step 2: Submit a formal appeal
PEAK submits the appeal on your behalf. This includes an updated prior authorization form with enhanced clinical documentation: detailed visit notes, lab results, documented comorbidities, and a clinical narrative explaining why Zepbound is medically necessary for your specific situation.
Step 3: Request a peer-to-peer review (if needed)
If the appeal is denied, your PEAK clinician can request a peer-to-peer call with the insurance company's medical director. This is a direct conversation between physicians about your case. In many instances, insurers overturn denials after peer-to-peer review when they understand the full clinical context.
Step 4: Explore alternative pathways
If Zepbound remains denied after appeal and peer review, we discuss alternatives: switching to a covered GLP-1 medication (like Wegovy or Saxenda), manufacturer savings programs, or documentation strategies for future resubmission.
Understanding the appeal process
Most insurance plans allow at least one level of internal appeal, and many allow two. The appeal must be filed within a specific timeframe — typically 180 days from the denial date, though some plans allow less time. PEAK tracks these deadlines and ensures appeals are filed promptly.
The appeal process typically takes 30 days for a standard review, or 72 hours for an expedited review if your clinician attests that waiting could seriously jeopardize your health. We request expedited reviews when clinically appropriate.
Industry data suggests that roughly 50% of prior authorization denials are overturned on appeal, though success rates vary by insurer and denial reason. Denials based on incomplete documentation have higher overturn rates than denials based on step therapy or formulary restrictions.
Alternative coverage options
If your Zepbound appeal is ultimately unsuccessful, you have several pathways forward:
Switch to a covered alternative
Your plan may cover Wegovy (semaglutide) or Saxenda (liraglutide) even if it does not cover Zepbound. While these are different medications, they belong to the same GLP-1 class and have similar mechanisms of action. Your clinician will determine which alternative is clinically appropriate.
Manufacturer savings programs
Eli Lilly, the manufacturer of Zepbound, offers a savings card that can reduce out-of-pocket costs for commercially insured patients. Eligibility and discount amounts vary, and the program cannot be combined with government insurance plans like Medicare or Medicaid.
Out-of-pocket payment plans
Some patients choose to pay cash for Zepbound while continuing to appeal or while waiting for plan year changes. The list price can be high without insurance, though patient assistance programs may reduce this for qualifying individuals.
PEAK does not prescribe compounded tirzepatide as an alternative to brand-name Zepbound. We only prescribe FDA-approved medications for patient safety and efficacy assurance.
How PEAK helps with denials
Prior authorization denials are frustrating, and the appeals process can feel opaque. At PEAK, we treat insurance navigation as part of your clinical care — not an administrative afterthought.
Here's what that looks like:
We handle the paperwork. You do not need to call your insurance company, draft appeal letters, or coordinate between your clinician and the insurer. We manage the entire process and keep you informed at each step.
We escalate when needed. If a standard appeal is denied, we request peer-to-peer reviews. If peer review fails, we explore external review options or alternative medications. We do not treat a denial as the end of the conversation.
We document strategically. Our clinicians know what insurers look for in prior authorization submissions. We build your treatment plan in a way that creates a clear, evidence-based record for coverage decisions.
If your prior authorization is denied, we will contact you within one business day to explain the reason and outline next steps. You will not be left to handle the insurance process alone.
Important safety information: Zepbound carries a boxed warning about thyroid C-cell tumors (medullary thyroid carcinoma) based on animal studies. It is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Discuss your full medical history with your clinician before starting treatment.
PEAK accepts commercial insurance and TRICARE. We do not accept Medicare or Medicaid, including Medicare Advantage and Medicaid managed care plans.
